We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.88 | 1.19% | 1,094.99 | 1,056.35 | 1,100.00 | 1,100.08 | 1,079.0855 | 1,087.89 | 282,365 | 01:00:00 |
From Jul 2019 to Jul 2024
By Matt Grossman
Regeneron Pharmaceuticals Inc. is initiating a Phase 3 trial for its double antibody cocktail to determine whether the cocktail can prevent Covid-19, the Tarrytown, N.Y.-based company said Monday.
The trial will evaluate whether Regeneron's cocktail, called REGN-COV2, can prevent infection among people who have had close exposure to the coronavirus that causes the disease.
Regeneron's trial will enroll 2,000 patients at approximately U.S. 100 sites.
The company has also moved into the Phase 2/3 portion of trials testing the cocktail's ability to treat people who have already contracted Covid-19. That effort will enroll approximately 2,900 patients, including hospitalized and non-hospitalized patients, at 150 sites in the U.S., Brazil, Mexico and Chile.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
July 06, 2020 07:33 ET (11:33 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
